Combining genomic biomarkers to guide immunotherapy in non-small cell lung cancer

CONCLUSIONS: The unexpected ICB responses in patients carrying resistance biomarkers in STK11, KEAP1 and EGFR were almost exclusively observed in patients with a high TMB. Considering these alterations in the context the TMB offered a highly specific combinatorial biomarker strategy for limiting overtreatment in NSCLC.PMID:38300729 | DOI:10.1158/1078-0432.CCR-23-4027

Source: Clinical Cancer Research - February 1, 2024 Category: Cancer & Oncology Authors: Joris van de Haar Joanne M Mankor Karlijn Hummelink Kim Monkhorst Egbert F Smit Lodewyk F A Wessels Edwin Cuppen Joachim G J V Aerts Emile E Voest Source Type: research